Asthma remission-Reference-Cited by-同舟云学术

Asthma remission

Published:2024-02-28 Issue: Volume: Page:e20240004
ISSN:1806-3756
Container-title:Jornal Brasileiro de Pneumologia
language:en
Short-container-title:J Bras Pneumol.

Author:

M O’Byrne1 Paul¹^ORCID

Affiliation:

1. 1. Firestone Institute for Respiratory Health and the Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Publisher

Sociedade Brasileira de Pneumologia e Tisiologia

Reference24 articles.

1. 1. Asher MI, García-Marcos L, Pearce NE, Strachan DP. Trends in worldwide asthma prevalence. Eur Respir J. 2020;56(6):2002094. https://doi.org/10.1183/13993003.02094-2020

2. 2. Global Initiative for Asthma [homepage on the internet]. Bethesda: Global Initiative for Asthma; c2023 [cited 2024 Jan 2]. Global Strategy for Asthma Management and Prevention (2023 update). Available from: http://www.ginasthma.org

3. 3. Chung KF, Wenzel S; European Respiratory Society/American Thoracic Society Severe Asthma International Guidelines Task Force. From the authors: International European Respiratory Society/American Thoracic Society guidelines on severe asthma. Eur Respir J. 2014;44(5):1378-1379. https://doi.org/10.1183/09031936.00120714

4. 4. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma [published correction appears in N Engl J Med. 2015 Apr 30;372(18):1777]. N Engl J Med. 2014;371(13):1198-1207. https://doi.org/10.1056/NEJMoa1403290

5. 5. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125-1132. https://doi.org/10.1164/rccm.201103-0396OC